Sermorelin acetate is a synthetic 29 amino acid peptide corresponding to the N-terminal biologically active fragment of human GHRH (GHRH 1-29). The N-terminal 29 amino acids of GHRH retain full biological activity at GHRH receptors, making sermorelin a pharmacologically active fragment with a shorter sequence than the full-length hormone.
GHRH Receptor Binding and Pituitary Research
Research has extensively examined sermorelin's binding interactions with the GHRH receptor, a class B GPCR expressed on pituitary somatotrophs. Studies have characterized its receptor binding kinetics, cAMP/PKA signaling activation, and downstream effects on GH gene transcription.
Growth Hormone Axis Modulation Research
A key research application of sermorelin involves its use as a diagnostic tool for assessing pituitary GH secretory capacity, including its use in GH stimulation testing protocols in research settings.
Age-Related GH Axis Research
Research has examined sermorelin in the context of age-associated decline in GH axis activity, investigating whether sermorelin administration can restore more physiological GH secretion patterns in aged experimental models.
• Walker RF (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308.
